BVS — Bioventus Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1665988 ·
Last close
$11.88
Market Cap
$804.85M
52W High
$12.30
52W Low
$7.81
ADV30
739,315
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 132,089,000 | 90,769,000 | 8,870,000 | 3,113,000 | 650,539,000 | 35,846,000 | 416,274,000 |
| Dec 2025 | 157,900,000 | 108,782,000 | 21,721,000 | 14,755,000 | 683,559,000 | 51,238,000 | 455,112,000 |
| Sep 2025 | 138,651,000 | 94,229,000 | 11,251,000 | 3,155,000 | 701,593,000 | 42,164,000 | 494,338,000 |
| Jun 2025 | 147,660,000 | 102,090,000 | 18,369,000 | 7,459,000 | 706,788,000 | 32,910,000 | 505,489,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$74,673,000
Investing CF
$-3,248,000
Financing CF
$-62,140,000
CapEx
$-2,562,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,929,000
Inventory
$82,236,000
Receivables
$128,303,000
ST Investments
—
EBIT TTM
$52,195,000
Pretax Income TTM
$25,709,000
Interest Exp TTM
$26,486,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$576,300,032
EBITDA
$80,897,000
Free Cash Flow
$63,310,876
Enterprise Value
$1,125,819,136
Total Cash
$35,846,000
Total Debt
$288,420,000
Shares Out
67,748,048
Trailing EPS
$0.41
Book Value
$2.79
ROE
16.5%
ROA
5.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 568,087,000 | 56,291,000 | 22,732,000 | 683,559,000 | 455,112,000 | — | 74,673,000 |
| Dec 2024 | 573,280,000 | 22,825,000 | -36,125,000 | 727,956,000 | 542,352,000 | — | 38,795,000 |
| Dec 2023 | 512,345,000 | 2,026,000 | -156,230,000 | 810,910,000 | 589,792,000 | — | 15,344,000 |
| Dec 2022 | 512,117,000 | -34,656,000 | -158,704,000 | 1,372,649,000 | 960,427,000 | — | -13,537,000 |
TTM Snapshot
Revenues TTM
$138,964,000
NetIncome TTM
$-5,165,000
OpCashFlow TTM
$0
Assets (Latest)
$727,956,000
Forward EPS
$0.91
Max Pain — expiry 2026-07-17
max pain strike: $10.00 · spot: $11.88 · call oi: 6,463 · put oi: 609
Expected Move to 2026-07-17:
±$0.68
(5.68%) —
implied range
$11.21 –
$12.56
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SIBN | SI-BONE, Inc. | $778.77M | $17.56 | — |
| BBNX | Beta Bionics, Inc. | $758.89M | $17.03 | — |
| SSII | SS Innovations International, Inc. | $758.50M | $3.79 | — |
| SGP | SpyGlass Pharma, Inc. | $752.92M | $22.52 | — |
| CBLL | Ceribell, Inc. | $742.16M | $19.56 | — |
News headlines (Yahoo Finance, 1h cache)
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
2026-07-10 22:14 · Yahoo
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
2026-07-09 13:40 · Yahoo
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
2026-07-08 16:00 · Yahoo
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
2026-07-08 13:55 · Yahoo
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
2026-07-07 12:20 · Yahoo
Zacks.com featured highlights include First Advantage, Bioventus and Ooma
2026-07-07 08:13 · Yahoo
3 Top Breakout Stocks to Snap Up for Big Upside in July 2026
2026-07-02 19:00 · Yahoo
Should Value Investors Buy Bioventus (BVS) Stock?
2026-06-25 13:40 · Yahoo
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
2026-06-23 13:40 · Yahoo
Are Investors Undervaluing Bioventus (BVS) Right Now?
2026-06-09 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.